Brighter recruits Global Product Manager - Diabetes.

08:30 / 12 December 2018 Brighter Press release

Brighter recruits Thor Sundsvik as Global Product Manager - Diabetes effective immediately. In this new role at Brighter, Thor will oversee and drive the commercialization of Brighter's unique data-driven and mobile diabetes management solutions. Primarily Actiste (® Diabetes Management as a Service.

Thor has extensive experience in sales and business development in the medtech and healthcare industry, particularly within digital solutions for treatment of chronic diseases in the home, and anesthesia. He has also been involved in the establishment of specialist clinics. Thor's most recent position was at Sedana Medical and he has previously held multiple senior positions within the Linde Group.

"Brighter is a truly innovative company with the best yet to come. Actiste, Brighter's flagship product within the therapeutic area Diabetes, not only simplifies the life for insulin-treated diabetics, but also enables healthcare providers to adopt a new, more future-oriented and productive, approach to treating chronic diseases. I look forward to be a driving force in this societal transformation," says Thor Sundsvik, Global Product Manager - Diabetes, Brighter.

Thor is assuming the role immediately and will be managing the ongoing commercialization of Actiste globally. Thor will also oversee and grow all Brighter's new diabetes-focused solutions being developed.

"Thor is a very knowledgeable individual with just the right profile and we are delighted that he has chosen to join us," says Truls Sjöstedt, Brighter's CEO and founder.

"Brighter is currently in a phase of rapid progress and in front of us we see a potential growth journey like no other. This entails new needs within the organization, not least when it comes to product ownership and sales as we intend to broaden our product portfolio significantly and eventually will take on additional chronic conditions besides diabetes," says Truls Sjöstedt.

For further information, please contact:

Truls Sjöstedt, CEO 
Phone: +46 709 73 46 00      

Henrik Norström, COO   
Phone: +46 733 40 30 45      

About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.

Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources.

About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop® - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole.

The Company's shares are listed on NASDAQOMX First North/BRIG ( Brighter's Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 - 684 211 00,,

Show as PDF

Show original from Cision


This information was distributed by Cision